Home
Home » companies

Exelixis

Exelixis Presents Cometriq (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer

Exelixis Presents Cometriq (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer
Yahoo/BusinessWire

Exelixis Announces Presentation of Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer

Exelixis Announces Presentation of Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer
Yahoo/BusinessWire

Tackling Cancer: Thyroid Cancer's Biggest Current and Upcoming Players

Tackling Cancer: Thyroid Cancer's Biggest Current and Upcoming Players
Motley Fool

Where Is Exelixis In The Cancer Therapeutics Market?

Where Is Exelixis In The Cancer Therapeutics Market?
Seeking Alpha

Why Exelixis Is Ready to Rebound

Why Exelixis Is Ready to Rebound
Motley Fool

Exelixis Earnings: Everything You Must Know Now

Exelixis Earnings: Everything You Must Know Now
Wall St. Cheat Sheet

What's Ahead for Exelixis?

What's Ahead for Exelixis?
Motley Fool

Genentech takes Exelixis drug into Phase III melanoma trial

Genentech takes Exelixis drug into Phase III melanoma trial
Bizjournals.com

JPMorgan Healthcare Conference Highlights: Exelixis

JPMorgan Healthcare Conference Highlights: Exelixis
Motley Fool

3 Biotech Stocks You Can Buy in 2013

3 Biotech Stocks You Can Buy in 2013
Motley Fool